**Supplementary Table 2. Baseline characteristics of PPI users and non-users in the prospective research cohort**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **PPI non-users (N=66)** | **PPI users (N=56)** | **p-value** | |
|  |  |  |  | |
| Age (years) | 56 ± 16 | 58 ± 14 | 0.68 | |
| Female | 27 (40.9%) | 36 (64.3%) | 0.01 | |
| Race |  |  | 0.32 | |
| *Black* | 49 (74.2%) | 33 (58.9%) |  | |
| *White* | 13 (19.7%) | 19 (35.7%) | |  |
| *Other* | 4 (6.0%) | 3 (5.4 %) |  | |
| BMI | 34.1 ± 9.5 | 35.3 ± 10.8 | 0.51 | |
|  |  |  |  | |
| Comorbidities |  |  |  | |
| HTN | 48 (72.7%) | 39 (69.6%) | 0.71 | |
| CHF | 6 (2.9 %) | 3 (5.4 %) | 0.43 | |
| DM | 35 (53.0%) | 24 (43.6%) | 0.3 | |
| CKD | 13 (19.7 %) | 7 (17.9%) | 0.28 | |
|  |  |  |  | |
| Medication use |  |  |  | |
| H2RA | 2 (3.0%) | 10 (17.3%) | 0.006 | |
|  |  |  |  | |

PPI=proton pump inhibitor, HTN=hypertension, CHF=congestive heart failure, DM=diabetes mellitus, CKD=chronic kidney disease, H2RA=histamine H2-receptor antagonists